Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Sutter East Bay Hospitals
mi
from
Berkley, CA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Sutter East Bay Hospitals
mi
from
Berkley, CA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Palm Springs Research Institute
mi
from
Hialeah, FL
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Palm Springs Research Institute
mi
from
Hialeah, FL
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
MCG Cancer Center
mi
from
Augusta, GA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
MCG Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Kansas University Medical Center
mi
from
Kansas City, KA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
University of Kentucky Markey Cancer Center Clinical Research Organization
mi
from
Lexington, KY
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
University of Kentucky Markey Cancer Center Clinical Research Organization
mi
from
Lexington, KY
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Nevada Cancer Institute
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Montefiore Medical Center
mi
from
Bronx, NY
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Mid Dakota Clinical P.C. - Cancer Treatment and Research Center
mi
from
Bismarck, ND
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Mid Dakota Clinical P.C. - Cancer Treatment and Research Center
mi
from
Bismarck, ND
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Gabrail Cancer Center
mi
from
Canton, OH
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Pharma Resource
mi
from
East Providence, RI
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Pharma Resource
mi
from
East Providence, RI
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated:  3/29/2012
Virginia Commonwealth University
mi
from
Richmond, VA
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
A Phase 1, Open-Label, Multi-Center, Parallel Group Study to the Pharmacokinetics and Safety of Subcutaneous Azacitidine in Adult Cancer Patients With and Without Impaired Renal Function
Status: Enrolling
Updated: 3/29/2012
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Carl T. Hayden VA Medical Center
mi
from
Phoenix, AZ
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Carl T. Hayden VA Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock
mi
from
No. Little Rock, AR
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock
mi
from
No. Little Rock, AR
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Loma Linda
mi
from
Loma Linda, CA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Loma Linda
mi
from
Loma Linda, CA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Connecticut Health Care System
mi
from
West Haven, CT
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Connecticut Health Care System
mi
from
West Haven, CT
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Bay Pines
mi
from
Bay Pines, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Bay Pines
mi
from
Bay Pines, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Miami
mi
from
Miami, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Miami
mi
from
Miami, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
James A. Haley Veterans Hospital, Tampa
mi
from
Tampa, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
James A. Haley Veterans Hospital, Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Richard Roudebush VA Medical Center, Indianapolis
mi
from
Indianapolis, IN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Richard Roudebush VA Medical Center, Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Iowa City
mi
from
Iowa City, IA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Iowa City
mi
from
Iowa City, IA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Maryland Health Care System, Baltimore
mi
from
Baltimore, MD
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Maryland Health Care System, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Jamaica Plain Campus
mi
from
Boston, MA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Jamaica Plain Campus
mi
from
Boston, MA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Minneapolis
mi
from
Minneapolis, MN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Kansas City MO
mi
from
Kansas City, MO
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Kansas City MO
mi
from
Kansas City, MO
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, St Louis
mi
from
St Louis, MO
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, St Louis
mi
from
St Louis, MO
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Omaha
mi
from
Omaha, NE
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Omaha
mi
from
Omaha, NE
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA New Jersey Health Care System, East Orange
mi
from
East Orange, NJ
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA New Jersey Health Care System, East Orange
mi
from
East Orange, NJ
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
New Mexico VA Health Care System, Albuquerque
mi
from
Albuquerque, NM
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
New Mexico VA Health Care System, Albuquerque
mi
from
Albuquerque, NM
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Western New York Healthcare System at Buffalo
mi
from
Buffalo, NY
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Western New York Healthcare System at Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Durham
mi
from
Durham, NC
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Durham
mi
from
Durham, NC
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Cleveland
mi
from
Cleveland, OH
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Portland
mi
from
Portland, OR
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Portland
mi
from
Portland, OR
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Pittsburgh Health Care System
mi
from
Pittsburgh, PA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Pittsburgh Health Care System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Ralph H Johnson VA Medical Center, Charleston
mi
from
Charleston, SC
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Ralph H Johnson VA Medical Center, Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
WJB Dorn Veterans Hospital, Columbia
mi
from
Columbia, SC
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
WJB Dorn Veterans Hospital, Columbia
mi
from
Columbia, SC
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Memphis
mi
from
Memphis, TN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center
mi
from
Nashville, TN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA North Texas Health Care System, Dallas
mi
from
Dallas, TX
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA North Texas Health Care System, Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Zablocki VA Medical Center, Milwaukee
mi
from
Milwaukee, WI
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Zablocki VA Medical Center, Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Observational Study of Kibow Biotics in Chronic Kidney Failure Patients
Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Chronic Kidney Failure Patients, in Conjunction With Standardized Care of Treatment
Status: Enrolling
Updated:  5/2/2012
Thomas Jefferson University
mi
from
Philadelphia, PA
Observational Study of Kibow Biotics in Chronic Kidney Failure Patients
Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Chronic Kidney Failure Patients, in Conjunction With Standardized Care of Treatment
Status: Enrolling
Updated: 5/2/2012
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Observational Study of Kibow Biotics in Dialysis Patients
Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Dialysis Patients, in Conjunction With Standardized Care of Treatment
Status: Enrolling
Updated:  5/2/2012
Thomas Jefferson University
mi
from
Philadelphia, PA
Observational Study of Kibow Biotics in Dialysis Patients
Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Dialysis Patients, in Conjunction With Standardized Care of Treatment
Status: Enrolling
Updated: 5/2/2012
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis
Observational Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Dialysis Patients, in Conjunction With Standardized Care of Treatment
Status: Enrolling
Updated:  5/2/2012
Parkside Dialysis Clinic at Downstate Medical Center
mi
from
Brooklyn, NY
Observational Study of Kibow Biotics in Chronic Kidney Failure Patients on Dialysis
Observational Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Dialysis Patients, in Conjunction With Standardized Care of Treatment
Status: Enrolling
Updated: 5/2/2012
Parkside Dialysis Clinic at Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
A Multiple-Dose, Open-Label Pharmakokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Status: Enrolling
Updated:  5/4/2012
University of Alabama - Birmingham
mi
from
Birmingham, AL
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
A Multiple-Dose, Open-Label Pharmakokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Status: Enrolling
Updated: 5/4/2012
University of Alabama - Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials